High persistence rate at one year- follow-up of subcutaneous vedolizumab at standard dose after switching endovenous vedolizumab, even in those previously intensified: Results of a Spanish multicentre observational study Laura Andrés; Marisa Iborra; Raquel Vicente; Lara Arias; Pilar Nos; Ana Royo-Esteban; Beatriz Sicilia;

Evaluation of the transition from intravenous to subcutaneous vedolizumab in patients with inflammatory bowel disease Carmen Amor Costa; Cristina Suárez Ferrer; Laura García Ramírez; Eduardo Martín-Arranz; Joaquín Poza Cordón; José Luis Rueda García; María Sánchez Azofra; Irene González Diaz; Clara Amiama Roig; María Dolores Martín-Arranz;

Real-world experience of vedolizumab use in Colombian patients with inflammatory bowel disease¿EXVEDOCOL Viviana Parra; Sandra Cifuentes; Sandra Avendaño; Enrique Ponce de León; Cristian Florez; Gustavo Reyes; Fabian Puentes; Manuel Ballesteros; Edilberto Nuñez; Federico Gómez; Juan Ricardo Márquez;